SCHEMBL1222092

SCHEMBL1222092

O=C(OC1C2CC3CC(C2)CC1C3)N1CCC2(CC1)CNCc1ccccc12

nearest known ligand 0.53

Predicted protein targets (top 4)

geneUniProtsupporting neighboursconfidence
HSD11B1 P28845 18/20 0.53
KCNH2 Q12809 1/20 0.39
HDAC1 Q13547 1/20 0.39
HSD11B2 P80365 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1223289 0.83 HSD11B1 (0.55) HSD11B1KCNH2HDAC1HSD11B2
SCHEMBL1222270 0.81 HSD11B1 (0.73) HSD11B1HSD11B2
SCHEMBL4110065 0.80 HSD11B1 (0.55) HSD11B1HSD11B2
SCHEMBL1223770 0.78 HSD11B1 (0.52) HSD11B1KCNH2
SCHEMBL4115045 0.77 HSD11B1 (0.41) HSD11B1KCNH2HDAC1HSD11B2
SCHEMBL652213 0.77 MAPK1 (0.46) KCNH2HDAC1
SCHEMBL652214 0.77 MAPK1 (0.46) KCNH2HDAC1
SCHEMBL654094 0.76 KCNH2 (0.47) HSD11B1KCNH2HDAC1
SCHEMBL654095 0.76 KCNH2 (0.47) HSD11B1KCNH2HDAC1
SCHEMBL1222439 0.76 HSD11B1 (0.50) HSD11B1HDAC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8927715-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-8927715-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-8927715-B2 Inhibitors of 11β-hydroxysteroid dehydrogenase type 1 VITAE PHARMACEUTICALS, INC. (US) 2015-01-06 US disclosed
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. 2011-02-10 US disclosed
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. 2011-02-10 US disclosed
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. 2011-02-10 US disclosed
WO-2008024497-A2 INHIBITORS OF 11β -HYDROXYSTEROID DEHYDROGENASE TYPE 1 VITAE PHARMACEUTICALS, INC. (US) 2008-02-28 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110034455-A1 INHIBITORS OF 11BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 HSD11B1, HSD17B1, HSD11B2 HSD11B1 1/4885KCNH2 4278/4885HDAC1 122/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.